<DOC>
	<DOCNO>NCT00019318</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness depsipeptide treat patient solid tumor standard therapy exists .</brief_summary>
	<brief_title>Depsipeptide Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxic effect maximum tolerate dose ( MTD ) depsipeptide patient incurable solid tumor ( per 3/29/00 notification , patient cutaneous T-cell lymphoma accrue ) . II . Determine antineoplastic activity depsipeptide patient . OUTLINE : This dose escalation , multicenter study . Patients receive depsipeptide IV 4 hour day 1 5 . Treatment continue every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos depsipeptide . If 2 6 patient experience dose-limiting toxicity give dose level , escalation cease maximum tolerate dose define previous dose level . PROJECTED ACCRUAL : A maximum 48 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm incurable solid tumor ( per 3/29/00 notification , patient cutaneous Tcell lymphoma accrue ) No know standard therapy disease potentially curative definitely capable extend life expectancy No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Greater 12 week Hematopoietic : WBC great 3,500/mm3 Platelet count great 100,000/mm3 PT/PTT great 1.1 time upper limit normal ( ULN ) Hepatic : Bilirubin le 1.5 ULN AST less 3 time ULN Renal : Creatinine le 1.5 time ULN Cardiovascular : Cardiogram must perform within 1 month protocol registration No class III/IV heart disease Ejection fraction least 45 % MUGA Echo Other : HIV negative No recent weight loss great 10 % average body weight Oral intake least 1,200 calories/day No uncontrolled infection Not pregnant nursing Fertile patient must use effective contraception No serious concurrent illness seizure disorder , uncontrolled hypertension , myelodysplastic syndrome PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosourea mitomycin ) No prior doxorubicin total dose great 360 mg/m2 Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiation therapy depsipeptide No prior radiation great 25 % bone marrow Surgery : At least 21 day since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2001</verification_date>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
</DOC>